 |
|
Extended Surgical Adjuvant Thiotepa for Mammary Carcinoma
William L. Donegan, MD
AMA Arch Surg. 1974;109(2):187-192.
Abstract
A clinical trial was conducted to evaluate protracted systemic thiotepa as an adjuvant to radical mastectomy for treatment of operable carcinoma of the breast. Patients were randomized to have the operation (controls) or the operation plus a year of adjuvant therapy beginning at the time of surgery. Seventy-five controls and 90 treated patients have been observed from one to ten years. It was not possible to establish from this trial that thiotepa used in this manner was of value as a surgical adjuvant. Local recurrence was reduced but recurrence overall was not altered, either in its frequency or time of appearance. A notable trend associated with treatment was improved disease-free survival among treated patients without axillary metastases, suggesting that the adjuvant may be most effective when residual cancer is minimal.
Author Affiliations
From the Ellis Fischel State Cancer Hospital and Cancer Research Center, Columbia, Mo.
Footnotes
Accepted for publication April 2, 1974.
Read before the 31st annual meeting of the Central Surgical Association, Cincinnati, March 7, 1974.
Reprint requests to Ellis Fischel State Cancer Hospital and Cancer Research Center, Business Loop 70 and Garth Ave, Columbia, MO 65201 (Dr. Donegan).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Perspectives in the Treatment of Breast Cancer: 1976
YOUNG et al.
ANN INTERN MED 1977;86:784-798.
ABSTRACT
Adjuvant Chemotherapy for Cancer: A Point of View
Jamieson and Ludbrook
Arch Surg 1977;112:119-120.
ABSTRACT
Systemic Therapy for Metastatic Breast Cancer
HASKELL et al.
ANN INTERN MED 1977;86:68-80.
ABSTRACT
|
